By combining the agents ruxolitinib and ibrutinib, the hope is that not only will the response rate against chronic GVHD increase but also will the duration of involvement decrease by targeting GVHD from both the JAK and BTK pathways. The gene discussed is BTK; the disease is chronic graft versus host disease.